351 related articles for article (PubMed ID: 37174744)
41. Mitotic DNA damage response: Polo-like kinase-1 is dephosphorylated through ATM-Chk1 pathway.
Lee HJ; Hwang HI; Jang YJ
Cell Cycle; 2010 Jun; 9(12):2389-98. PubMed ID: 20581453
[TBL] [Abstract][Full Text] [Related]
42. PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy.
Tan J; Li Z; Lee PL; Guan P; Aau MY; Lee ST; Feng M; Lim CZ; Lee EY; Wee ZN; Lim YC; Karuturi RK; Yu Q
Cancer Discov; 2013 Oct; 3(10):1156-71. PubMed ID: 23887393
[TBL] [Abstract][Full Text] [Related]
43. Promotion of mitosis by activated protein kinase B after DNA damage involves polo-like kinase 1 and checkpoint protein CHFR.
Shtivelman E
Mol Cancer Res; 2003 Nov; 1(13):959-69. PubMed ID: 14638868
[TBL] [Abstract][Full Text] [Related]
44. The natural product Aristolactam AIIIa as a new ligand targeting the polo-box domain of polo-like kinase 1 potently inhibits cancer cell proliferation.
Li L; Wang X; Chen J; Ding H; Zhang Y; Hu TC; Hu LH; Jiang HL; Shen X
Acta Pharmacol Sin; 2009 Oct; 30(10):1443-53. PubMed ID: 19801998
[TBL] [Abstract][Full Text] [Related]
45. The Plk1 Polo box domain mediates a cell cycle and DNA damage regulated interaction with Chk2.
Tsvetkov LM; Tsekova RT; Xu X; Stern DF
Cell Cycle; 2005 Apr; 4(4):609-17. PubMed ID: 15876876
[TBL] [Abstract][Full Text] [Related]
46. Therapeutic relevance of the protein phosphatase 2A in cancer.
Cunningham CE; Li S; Vizeacoumar FS; Bhanumathy KK; Lee JS; Parameswaran S; Furber L; Abuhussein O; Paul JM; McDonald M; Templeton SD; Shukla H; El Zawily AM; Boyd F; Alli N; Mousseau DD; Geyer R; Bonham K; Anderson DH; Yan J; Yu-Lee LY; Weaver BA; Uppalapati M; Ruppin E; Sablina A; Freywald A; Vizeacoumar FJ
Oncotarget; 2016 Sep; 7(38):61544-61561. PubMed ID: 27557495
[TBL] [Abstract][Full Text] [Related]
47. Proteomic screen defines the Polo-box domain interactome and identifies Rock2 as a Plk1 substrate.
Lowery DM; Clauser KR; Hjerrild M; Lim D; Alexander J; Kishi K; Ong SE; Gammeltoft S; Carr SA; Yaffe MB
EMBO J; 2007 May; 26(9):2262-73. PubMed ID: 17446864
[TBL] [Abstract][Full Text] [Related]
48. Inhibitory role of Plk1 in the regulation of p73-dependent apoptosis through physical interaction and phosphorylation.
Koida N; Ozaki T; Yamamoto H; Ono S; Koda T; Ando K; Okoshi R; Kamijo T; Omura K; Nakagawara A
J Biol Chem; 2008 Mar; 283(13):8555-63. PubMed ID: 18174154
[TBL] [Abstract][Full Text] [Related]
49. Regulation of cell apoptosis and proliferation in pancreatic cancer through PI3K/Akt pathway via Polo-like kinase 1.
Mao Y; Xi L; Li Q; Cai Z; Lai Y; Zhang X; Yu C
Oncol Rep; 2016 Jul; 36(1):49-56. PubMed ID: 27220401
[TBL] [Abstract][Full Text] [Related]
50. Polo-like kinase 1 inhibits the activity of positive transcription elongation factor of RNA Pol II b (P-TEFb).
Jiang L; Huang Y; Deng M; Liu T; Lai W; Ye X
PLoS One; 2013; 8(8):e72289. PubMed ID: 23977272
[TBL] [Abstract][Full Text] [Related]
51. Identification of potential Plk1 targets in a cell-cycle specific proteome through structural dynamics of kinase and Polo box-mediated interactions.
Bibi N; Parveen Z; Rashid S
PLoS One; 2013; 8(8):e70843. PubMed ID: 23967120
[TBL] [Abstract][Full Text] [Related]
52. Participation of PLK1 and FOXM1 in the hyperplastic proliferation of pulmonary artery smooth muscle cells in pulmonary arterial hypertension.
Wilson JL; Wang L; Zhang Z; Hill NS; Polgar P
PLoS One; 2019; 14(8):e0221728. PubMed ID: 31437238
[TBL] [Abstract][Full Text] [Related]
53. A PIM-CHK1 signaling pathway regulates PLK1 phosphorylation and function during mitosis.
Adam K; Cartel M; Lambert M; David L; Yuan L; Besson A; Mayeux P; Manenti S; Didier C
J Cell Sci; 2018 Aug; 131(15):. PubMed ID: 29976560
[TBL] [Abstract][Full Text] [Related]
54. The RNA helicase/transcriptional co-regulator, p68 (DDX5), stimulates expression of oncogenic protein kinase, Polo-like kinase-1 (PLK1), and is associated with elevated PLK1 levels in human breast cancers.
Iyer RS; Nicol SM; Quinlan PR; Thompson AM; Meek DW; Fuller-Pace FV
Cell Cycle; 2014; 13(9):1413-23. PubMed ID: 24626184
[TBL] [Abstract][Full Text] [Related]
55. Current assessment of polo-like kinases as anti-tumor drug targets.
Craig SN; Wyatt MD; McInnes C
Expert Opin Drug Discov; 2014 Jul; 9(7):773-89. PubMed ID: 24819909
[TBL] [Abstract][Full Text] [Related]
56. Cell type-- dependent effects of Polo-like kinase 1 inhibition compared with targeted polo box interference in cancer cell lines.
Fink J; Sanders K; Rippl A; Finkernagel S; Beckers TL; Schmidt M
Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3189-97. PubMed ID: 18089713
[TBL] [Abstract][Full Text] [Related]
57. Playing polo during mitosis: PLK1 takes the lead.
Combes G; Alharbi I; Braga LG; Elowe S
Oncogene; 2017 Aug; 36(34):4819-4827. PubMed ID: 28436952
[TBL] [Abstract][Full Text] [Related]
58. Multiple Roles of PLK1 in Mitosis and Meiosis.
Kalous J; Aleshkina D
Cells; 2023 Jan; 12(1):. PubMed ID: 36611980
[TBL] [Abstract][Full Text] [Related]
59. Transcription factors as master regulator for cancer stemness: remove milk from fox?
Nakano I
Expert Rev Anticancer Ther; 2014 Aug; 14(8):873-5. PubMed ID: 25017123
[TBL] [Abstract][Full Text] [Related]
60. Structure-activity and mechanistic studies of non-peptidic inhibitors of the PLK1 polo box domain identified through REPLACE.
Craig SN; Baxter M; Chapagai D; Stafford JM; Nurmemmedov E; Altomare D; Wyatt MD; McInnes C
Eur J Med Chem; 2022 Jan; 227():113926. PubMed ID: 34735919
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
